Schrodinger is trading at $29.12, up 4.20%, as its November 4 results and raised outlook offer the clearest explanation for the November 5 gain. - Third-quarter revenue was $64.5 million, beating estimates. - Management raised full-year ACV growth guidance to 12–17% and drug-discovery revenue guidance to $75–85 million; the revenue outlook increase reflects a milestone payment from Structure Therapeutics. - Shares rose despite sharply lower major indexes, rather than following the broader market.